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Background
Carbamazepine (CBZ) is associated with the severe cuta-
neous drug reaction Stevens-Johnson Syndrome/toxic
epidermal necrolysis (SJS/TEN). CBZ-SJS/TEN has been
associated with HLA-B*15:02 carriage and specific T-cell
clonotypes. We aimed to characterize the interactions
between specific T-cell receptor (TCR) clonotypes,
HLA-B*15:02 and CBZ.
Methods
Peripheral blood mononuclear cells (PBMCs) were
isolated from patients with CBZ-SJS/TEN and healthy
controls, stimulated with 10ug/mL CBZ (Sigma, cat. no.
C4024-5G) and cultured over a 9-14 day period. RNA
was isolated at various time points and TCR V subtypes
were assessed using digital droplet PCR (Bio-Rad
QX100 droplet digital PCR system). Drug specific T-cell
INF and granulysin responses were assessed by ELISpot
and ICS. In silico modelling was used to examine the
interaction between the known specific TCR V and V
chains, CBZ and HLA-B*15:02.
Results
CBZ specific T-cell INF and granulysin responses were
detected many years following the original SJS/TEN
reaction. Expansion of specific TCR CDR3 sequences
was confirmed in CBZ SJS/TEN patient cultures.
In silico modelling of the CBZ-HLA-B*15:02-TCR inter-
action suggests that CBZ binds non-covalently in the P4
binding pocket of the HLA-B*15:02 antigen binding
cleft in a site that is typically occupied with bound
peptide.
Conclusions
These findings raise two non-mutually exclusive possibili-
ties: 1) CBZ may block peptide binding and be presented
by HLA-B*15:02 in a solvent exposed manner available for
direct recognition by the TCR, 2) CBZ binding the central
portion of the HLA-B*15:02 antigen binding cleft may per-
mit long peptides to bind conventionally at the peptide
termini (in the A and F pockets) and bulge over the drug
in the central residues to permit indirect recognition of
CBZ (peptide mediated TCR contact).
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